- Conditions
- Metastatic Solid Tumors
- Interventions
- SLV-324 intravenous (IV infusion)
- Drug
- Lead sponsor
- Solve Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Newport Beach, California • St Louis, Missouri • Cleveland, Ohio + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 6,731
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Graft Failure, Sickle Cell Disease, Hemoglobinopathies
- Interventions
- Alemtuzumab, Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Cyclophosphamide, Sirolimus, Tacrolimus, Mycophenolate Mofetil, Plerixafor (mozobil)
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Mobile Application, Treatment as Usual (TAU)
- Behavioral
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Manchester, New Hampshire
- Conditions
- Opiate Addiction
- Interventions
- Depot naltrexone, Treatment as Usual (TAU)
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Age-Related Osteoporosis
- Interventions
- Teriparatide, Alendronate
- Drug
- Lead sponsor
- Madhumathi Rao
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Sleep Initiation and Maintenance Disorders, Insomnia
- Interventions
- GW679769
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 13
- States / cities
- Glendale, Arizona • Glendale, California • Hallandale, Florida + 10 more
- Conditions
- Lipodystrophy, Diabetes, Hyperlipidemia
- Interventions
- Metreleptin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Months to 98 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
- Interventions
- High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
- Conditions
- Hypertension
- Interventions
- Group medical visits
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Aldesleukin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • San Jose, California + 10 more
- Conditions
- Keratitis, Corneal Ulcer
- Interventions
- PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial Tears
- Combination Product · Other
- Lead sponsor
- Peschke GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
- Conditions
- Healthy
- Interventions
- Entolimod, Placebo, Influenza vaccine
- Drug
- Lead sponsor
- Robert J. Pignolo
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy
- Interventions
- MK-7262, Enlicitide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Propranolol Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Itepekimab (SAR440340), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 64
- States / cities
- Chandler, Arizona • Tucson, Arizona • La Palma, California + 51 more
- Conditions
- Pancreatitis
- Interventions
- Administration of Lactated Ringer's (LR) Solution
- Other
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 6
- States / cities
- Evanston, Illinois • Highland Park, Illinois • Skokie, Illinois + 3 more
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
- Interventions
- Carboplatin, Cisplatin, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Biospecimen Collection, Diagnostic Imaging
- Drug · Procedure · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
- Interventions
- Imexon
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Rochester, New York
- Conditions
- Dermatitis Atopic
- Interventions
- Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
- Conditions
- Nutrition, Fatty Acids, Omega-3, Cognition, Resilience, Psychological, Psychology, Military
- Interventions
- Phospholipid-bound omega-3 supplement, Placebo supplement
- Dietary Supplement
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- Not listed
- Enrollment
- 555 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Fort Benning, Georgia • Bethesda, Maryland • Charleston, South Carolina
- Conditions
- Hypercholesterolemia
- Interventions
- alirocumab SAR236553 (REGN727)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Healthy Volunteers
- Interventions
- Viagra 50 mg tablet, Formulation B ODT tablet 50 mg, Formulation C ODT tablet 50 mg, Formulation D ODT tablet 50 mg
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Multiple Sclerosis
- Interventions
- armodafinil
- Drug
- Lead sponsor
- University of Missouri, Kansas City
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Depression, Anxiety, Substance Use Disorder (SUD), Post Traumatic Stress Disorder
- Interventions
- Microcurrent Neurofeedback (MCN), Standard Care for Substance Use Disorder
- Device · Behavioral
- Lead sponsor
- University of Alabama, Tuscaloosa
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Tuscaloosa, Alabama